Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.

Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C.

Infect Dis Ther. 2018 May 14. doi: 10.1007/s40121-018-0201-6. [Epub ahead of print] Review.

2.

Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease.

Punekar YS, Riley JH, Lloyd E, Driessen M, Singh SJ.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 22;12:2487-2506. doi: 10.2147/COPD.S100204. eCollection 2017. Review.

3.

Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.

Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW.

Respir Res. 2017 May 8;18(1):86. doi: 10.1186/s12931-017-0566-1. Review.

4.

Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset.

Mueller S, Wilke T, Bechtel B, Punekar YS, Mitzner K, Virchow JC.

Respir Med. 2017 Jan;122:1-11. doi: 10.1016/j.rmed.2016.11.008. Epub 2016 Nov 4.

PMID:
27993284
5.

Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.

Landis SH, Wurst K, Le HV, Bonar K, Punekar YS.

COPD. 2017 Feb;14(1):80-85. doi: 10.1080/15412555.2016.1240159. Epub 2016 Nov 7.

PMID:
27819513
6.

Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study.

Punekar YS, Naya I, Small M, Holbrook T, Wood R, Mullerova H, Valle M.

J Med Econ. 2017 Jan;20(1):28-36. Epub 2016 Aug 26.

PMID:
27564685
7.

Prevalence and burden of dyspnoea among COPD patients in Japan.

Small M, Holbrook T, Wood R, Mullerova H, Naya I, Punekar YS.

Int J Clin Pract. 2016 Aug;70(8):676-81. doi: 10.1111/ijcp.12833. Epub 2016 Jul 11.

PMID:
27396989
8.

The effect of umeclidinium added to inhaled corticosteroid/long-acting ╬▓2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.

Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA.

NPJ Prim Care Respir Med. 2016 Jun 23;26:16031. doi: 10.1038/npjpcrm.2016.31.

9.

Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, Mannino DM, Ichinose M, Punekar Y.

PLoS One. 2016 Apr 19;11(4):e0152618. doi: 10.1371/journal.pone.0152618. eCollection 2016.

10.

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK.

Punekar YS, Roberts G, Ismaila A, O'Leary M.

Cost Eff Resour Alloc. 2015 Dec 12;13:22. doi: 10.1186/s12962-015-0048-6. eCollection 2015.

11.

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.

Ismaila AS, Huisman EL, Punekar YS, Karabis A.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 16;10:2495-517. doi: 10.2147/COPD.S92412. eCollection 2015. Review.

12.
13.

Burden Of Symptomatic Copd Patients In Spain: Data From Continuing To Confront Copd International Patient Survey 2012-2013.

Huerta A, Landis SH, Punekar YS.

Value Health. 2015 Nov;18(7):A499. doi: 10.1016/j.jval.2015.09.1405. Epub 2015 Oct 20. No abstract available.

14.

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.

Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 9;10:1863-81. doi: 10.2147/COPD.S87082. eCollection 2015. Review.

15.

Systematic Review of the Association Between Laboratory- and Field-Based Exercise Tests and Lung Function in Patients with Chronic Obstructive Pulmonary Disease.

Bell M, Fotheringham I, Punekar YS, Riley JH, Cockle S, Singh SJ.

Chronic Obstr Pulm Dis. 2015 Jul 8;2(4):321-342. doi: 10.15326/jcopdf.2.4.2014.0157. Review.

16.

Comparison of laboratory- and field-based exercise tests for COPD: a systematic review.

Fotheringham I, Meakin G, Punekar YS, Riley JH, Cockle SM, Singh SJ.

Int J Chron Obstruct Pulmon Dis. 2015 Mar 19;10:625-43. doi: 10.2147/COPD.S70518. eCollection 2015. Review.

17.

Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.

Srivastava K, Thakur D, Sharma S, Punekar YS.

Pharmacoeconomics. 2015 May;33(5):467-88. doi: 10.1007/s40273-015-0252-4. Review.

PMID:
25663178
18.

Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients.

Punekar YS, Roberts G, Ismaila A, O'Leary M.

Value Health. 2014 Nov;17(7):A595. doi: 10.1016/j.jval.2014.08.2053. Epub 2014 Oct 26. No abstract available.

19.

Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK.

Ismaila A, Roberts G, Punekar YS, O'Leary M.

Value Health. 2014 Nov;17(7):A595. doi: 10.1016/j.jval.2014.08.2052. Epub 2014 Oct 26. No abstract available.

20.

Comparative Efficacy of Umeclidinium Bromide Versus Other Long-Acting Anticholinergic Monotherapies as Treatments for Copd Patients.

Ismaila A, Huisman E, Punekar YS.

Value Health. 2014 Nov;17(7):A588-9. doi: 10.1016/j.jval.2014.08.2013. Epub 2014 Oct 26. No abstract available.

21.

Treatment evolution after COPD diagnosis in the UK primary care setting.

Wurst KE, Punekar YS, Shukla A.

PLoS One. 2014 Sep 2;9(9):e105296. doi: 10.1371/journal.pone.0105296. eCollection 2014.

22.

Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study.

Punekar YS, Wurst K, Shukla A.

COPD. 2015 Jun;12(3):267-75. doi: 10.3109/15412555.2014.933953. Epub 2014 Aug 5.

PMID:
25093809
23.

COPD management costs according to the frequency of COPD exacerbations in UK primary care.

Punekar YS, Shukla A, M├╝llerova H.

Int J Chron Obstruct Pulmon Dis. 2014;9:65-73. doi: 10.2147/COPD.S54417. Epub 2014 Jan 9. Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:247.

24.
25.

Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.

Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS.

Eur J Health Econ. 2012 Dec;13(6):801-9. doi: 10.1007/s10198-011-0335-x. Epub 2011 Jul 1.

PMID:
21720868
26.

Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.

Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, Fenwick E.

Value Health. 2011 Jan;14(1):15-23. doi: 10.1016/j.jval.2010.10.016.

27.

Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.

Punekar YS, Sunderland T, Hawkins N, Lindsay J.

Value Health. 2010 Mar-Apr;13(2):188-95. doi: 10.1111/j.1524-4733.2009.00658.x. Epub 2009 Oct 26.

28.

Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.

Punekar YS, Hawkins N.

Eur J Health Econ. 2010 Feb;11(1):67-76. doi: 10.1007/s10198-009-0199-5. Epub 2009 Oct 21.

PMID:
19844750
29.

Establishing the sequential progression of multiple allergic diagnoses in a UK birth cohort using the General Practice Research Database.

Punekar YS, Sheikh A.

Clin Exp Allergy. 2009 Dec;39(12):1889-95. doi: 10.1111/j.1365-2222.2009.03366.x. Epub 2009 Oct 7.

PMID:
19817751
30.

Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices.

Punekar YS, Sheikh A.

Clin Exp Allergy. 2009 Aug;39(8):1209-16. doi: 10.1111/j.1365-2222.2009.03248.x. Epub 2009 Apr 17.

PMID:
19400899
31.

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.

Tsai HH, Punekar YS, Morris J, Fortun P.

Aliment Pharmacol Ther. 2008 Nov 15;28(10):1230-9. doi: 10.1111/j.1365-2036.2008.03839.x. Epub 2008 Aug 24.

32.

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.

Lindsay J, Punekar YS, Morris J, Chung-Faye G.

Aliment Pharmacol Ther. 2008 Jul;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x. Epub 2008 Apr 11.

33.

Implications of chronic obstructive pulmonary disease (COPD) on patients' health status: a western view.

Punekar YS, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M.

Respir Med. 2007 Mar;101(3):661-9. Epub 2007 Jan 2.

34.

Survey of pharmacist collaborative drug therapy management in hospitals.

Thomas J 3rd, Bharmal M, Lin SW, Punekar Y.

Am J Health Syst Pharm. 2006 Dec 15;63(24):2489-99.

PMID:
17158697
35.

Progress of pharmacist collaborative practice: status of state laws and regulations and perceived impact of collaborative practice.

Punekar Y, Lin SW, Thomas J 3rd.

J Am Pharm Assoc (2003). 2003 Jul-Aug;43(4):503-10.

PMID:
12952315

Supplemental Content

Loading ...
Support Center